Diagnosis and Treatment of Multifocal Motor Neuropathy with Conduction Block
Intravenous immunoglobulin (IVIg) is the first-line and only proven effective treatment for multifocal motor neuropathy (MMN), typically requiring high doses (2 g/kg) every 4-8 weeks for maintenance therapy 1, 2.
Diagnostic Criteria
The diagnosis of MMN requires a combination of clinical, electrophysiological, and laboratory findings:
Clinical Features
- Asymmetric, progressive limb weakness affecting motor nerves only, without sensory loss
- Upper extremity predominance with distal > proximal weakness pattern
- Typically affects middle-aged adults (median onset age 42 years) with male predominance (2-3:1) 3, 4
- Slowly progressive or stepwise deterioration over months to years
Electrophysiological Findings
Motor conduction blocks are the hallmark finding, but standard criteria may be overly restrictive. In the context of clinically suspected MMN, conduction block should be defined as 5:
- Reduction in negative peak area >23% across distal segments or >29% across proximal segments
- Reduction in amplitude >32% across distal segments or >33% across proximal segments
- Approximately one-third of conduction blocks occur proximally, which can be missed on routine studies 5
The traditional stringent criteria would miss over 30% of IVIg-responsive patients 5. Temporal dispersion should not automatically exclude the diagnosis, as this may be overly restrictive 5.
Laboratory Testing
- Anti-GM1 IgM antibodies are present in 50-54% of patients 4, 3
- Testing for GM1/galactocerebroside (GM1/GalC) complexes can improve antibody detection sensitivity 4
- CSF protein may be mildly elevated but is not required for diagnosis
Imaging Studies
- Nerve ultrasound and MRI can reveal non-uniform nerve enlargement at roots, plexuses, or peripheral segments, helpful in diagnostic dilemmas 4, 2
Treatment Algorithm
Initial Treatment
Start IVIg at 2 g/kg divided over 2-5 days 1, 2:
- 91% of patients show improvement with IVIg 3
- Response is dose- and frequency-dependent 1
- Gammagard Liquid 10% is FDA-approved specifically for MMN 1
Maintenance Therapy
Continue IVIg every 4-8 weeks indefinitely 1:
- 74% of patients require ongoing maintenance therapy at long-term follow-up 3
- Subcutaneous immunoglobulin (SCIg) given weekly at equivalent doses is equally effective with fewer side effects 4, 1
- Monitor using disease-specific scales like MMN-Rasch-built overall disability scale 4
Treatment Resistance
If response decreases over time despite higher/more frequent IVIg dosing 1:
- Cyclophosphamide has shown some benefit in case reports 1
- Rituximab has demonstrated variable results in case reports 1
- Complement inhibitor eculizumab may be a potential future option but requires further study 4
Critical Pitfalls to Avoid
Do NOT use corticosteroids or plasma exchange - these are ineffective in MMN and may worsen the condition, despite being effective in chronic inflammatory demyelinating polyneuropathy (CIDP) 1, 6.
Beware of misdiagnosis: MMN is frequently confused with:
- Motor neuron disease/ALS (most common misdiagnosis) 7
- CIDP or Lewis-Sumner syndrome (MADSAM neuropathy) 6
- Over 70% of patients receive differential diagnoses during evaluation 7
- Many patients with initial MMN diagnosis codes actually have alternative disorders 7
Undertreatment is common: Many diagnosed patients do not receive IVIg, suggesting either misattribution of diagnosis codes or lack of access to guideline-recommended treatment 7.
Long-Term Prognosis
Despite maintenance IVIg therapy, slight progression of neurological deficits occurs over time in most patients 2, 3. The median disease duration from onset to diagnosis is approximately 25 months 3, emphasizing the importance of early recognition and treatment initiation. More effective immunotherapy, particularly complement inhibition, is needed to halt long-term progression 2.